Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay

Abstract

The study objective was to determine the effectiveness of a phenotypic chemoresponse assay in predicting response to chemotherapy measured by progression-free interval (PFI) in a retrospective series of ovarian cancer patients whose tumor specimens had been tested with the ChemoFx assay. A statistically significant correlation between assay prediction of response and PFI was observed in 256 cases with an exact or partial match between drug(s) assayed and received. In 135 cases with an exact match, the hazard ratio for progression of the resistant group was 2.9 (confidence interval [CI]: 1.4-6.3; P < 0.01) compared to the sensitive group and 1.7 (CI: 1.2-2.5) for the intermediate compared to the sensitive group. The median PFI for patients treated with drugs assayed as resistant was 9 months, 14 months for those with drugs assayed as intermediately sensitive, and PFI had not been achieved for those with drugs assayed as sensitive. These data indicate that the ChemoFx assay is predictive of PFI in ovarian cancer. As the majority of ovarian cancers display different degrees of response to different chemotherapy agents ex vivo, the incorporation of assay information into treatment selection has the potential to improve clinical outcomes in ovarian cancer patients.

Developing options for method of assessing the sensitivity of cells intracranial neoplasms to chemotherapeutics in vitro

“…Другие исследователи не смогли выявить пре-имуществ методов индивидуальной оценки хими-очувствительности перед протокольными и заняли отрицательную позицию [22,27,28]. Третьи авторы, установив лишь частичные преимущества в персо-нифицированном тестировании химиочувствитель-ности, заняли промежуточную позицию [22,27]. Нередко наблюдения по сопоставлению результатов in vitro и ex vivo были малочисленны, а если и име-ли представительную выборку, то не были аккуратно спланированы.…”

Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer

“…In a 2006 study, progression free intervals were nearly three times longer in ovarian cancer patients who received a drug(s) to which they had tested responsive by ChemoFx than in patients who received a drug(s) to which they had tested non-responsive by ChemoFx. 45 A 2010 study found that the median overall survival in patients with primary ovarian cancer was at least 33% higher for those receiving a drug to which their tumors were classified as responsive by ChemoFx than for those receiving a drug to which their tumors were classified as non-responsive by ChemoFx. 46 Finally, breast cancer patients whose tumors tested responsive to docetaxel/capecitabine (TX) by ChemoFx were three times more likely to reach pathological complete response (pCR) when treated with TX than those whose tumors tested non-responsive by ChemoFx.…”

An in vitro chemoresponse assay defines a subset of colorectal and lung carcinomas responsive to cetuximab

“…16 Results from ChemoFx can help to predict patient responses to chemotherapy for treatment of ovarian cancer and may be helpful to identify drugs to which tumors are non-responsive (NR). 17,18 Recently, we reported that testing for sensitivity to erlotinib, an EGFR tyrosine kinase inhibitor, in the ChemoFx DRM was feasible. In addition, the results from testing tumors from patients with NSCLC with erlotinib using the ChemoFx DRM were similar to published response rates for patients treated with erlotinib clinically, indicating that the ChemoFx DRM may be helpful to identify patients whose tumors may be responsive to erlotinib.…”